NEPHNasdaqSurgical & Medical Instruments & ApparatusUS GAAP · USD

Nephros, Inc

Nephros, Inc. develops and sells water filtration and ultrafiltration products used in healthcare and commercial settings. Its systems are designed to improve water quality and help reduce infection and contamination risks in hospitals, dialysis centers, and foodservice or hospitality facilities.

Kysy yhtiöstä
Liikevaihto18,8milj. USD
+32,7 %v/v
Liikevoitto (EBIT)1,1milj. USD
+19 000,0 %v/v
EBIT-marginaali6,1%
+6,1 %-yks.v/v
Nettotulos1,2milj. USD
+1 513,5 %v/v
Vapaa kassavirta1,6milj. USD
+390,7 %v/v

Tilikausi 2025 · muutos edellisvuodesta

Kehitys 2020–2025

−505101520milj. USD2020: 8,6 milj. USD2020: EBIT −4,3 milj. USD20202021: 10 milj. USD2021: EBIT −4,3 milj. USD20212022: 10,0 milj. USD2022: EBIT −4,3 milj. USD20222023: 14 milj. USD2023: EBIT −1,6 milj. USD20232024: 14 milj. USD2024: EBIT 0,01 milj. USD20242025: 19 milj. USD2025: EBIT 1,1 milj. USD2025191,1
LiikevaihtoLiikevoitto (EBIT)
Kysy Clarifolta: Nephros, Inc

Liiketoiminta

Osuus liikevaihdosta
Healthcare water filtration55 %

Ultrafilters and related products used in hospitals and medical facilities to reduce waterborne pathogens.

Dialysis water treatment15 %

Filtration products used in dialysis centers and dialysis equipment to remove biological contaminants.

Commercial water filtration25 %

Filters sold into foodservice, hospitality, convenience store, and industrial applications.

Services and support5 %

Installation, servicing, maintenance, and technical support for deployed systems.

Tuotteet

Raportoitu · osuus liikevaihdosta
97,1%FY2025100 %
  • Products97,1 %
  • Services2,8 %
  • Other Revenue0,1 %

Lähde: 10-K FY2025, yhtiön tuotelinjoittain raportoima liikevaihto (SEC XBRL). Osuudet on laskettu näytetyistä riveistä ja ne summautuvat 100 %:iin.

Asiakkaat

Nephros sells to hospitals, dialysis providers, and other healthcare facilities that need water filtration for infection control and clinical use. It also serves commercial customers such as hotels, restaurants, casinos, convenience stores, and food and beverage operators that want better water quality for consumption and equipment protection. The company relies on a mix of direct sales and distributors, especially in commercial markets.

Hospitals and other healthcare facilities

Buy ultrafilters for infection control, patient safety, and waterborne pathogen reduction.

Dialysis centers and dialysis equipment users

Buy filtration products for hemodialysis water and bicarbonate concentrate treatment.

Commercial foodservice and hospitality

Buy water filters for ice machines, beverage systems, and drinking water quality.

Convenience stores and restaurants

Buy filtration products to improve water taste, odor, and equipment performance.

Distributors and service partners

Buy and resell products or provide installation and service to end customers.

Strategia

Nephros is focused on growing sales of its water filtration products while controlling operating costs and preserving liquidity. Management is also working to expand distribution, strengthen service coverage, and support demand in both healthcare and commercial markets. Product acceptance, regulatory compliance, and the ability to maintain positive operating cash flow are central to the strategy.

Expand commercial distributionLyhyt aikaväli

Commercial growth now depends on new partners after the Donastar relationship ended.

Maintain and grow healthcare adoptionKeskipitkä aikaväli

Hospitals and dialysis centers are core end markets for the ultrafiltration platform.

Improve operating cash flowLyhyt aikaväli

The company wants to fund operations internally and reduce financing dependence.

Maantiede

Nephros is a U.S.-based company with corporate headquarters, research, manufacturing, and distribution facilities in New Jersey. The filings do not provide a country revenue split, but the business appears centered on the United States with commercial and healthcare customers served through direct sales and distribution partners. Geography matters because the company’s growth depends on building local service and distribution coverage in each market it enters.

Riskit

Nephros depends on third-party contractors and distributors to install, service, and sell its products, so execution failures can directly hurt revenue and reputation. The company also faces regulatory and product-compliance risk because its medically approved products are subject to FDA and other rules, while commercial demand can fluctuate with customer budgets, competition, and emergency-response buying patterns. As a smaller company, it also faces customer concentration, supply-chain dependence, and liquidity sensitivity if demand weakens.

Järjestetty vakavuuden mukaan
MatalaKohtalainenKorkeaMatalaKohtalainenKorkeaVaikutus →Todennäköisyys →Reliance on third-party contractors for installation and service1Dependence on new distribution partners in commercial markets2Regulatory compliance and FDA oversight3Supply-chain dependence on third-party product suppliers4Demand volatility in emergency-response sales5
Vaikutus on riskin vakavuus ja todennäköisyys sen toteutumisen todennäköisyys lähivuosina, molemmat arvioitu yhtiön raporttien perusteella. Numerot vastaavat listaa.
  1. Reliance on third-party contractors for installation and serviceVaikutus: KorkeaTodennäköisyys: Kohtalainen

    Poor service quality or delays can damage product performance, compliance, and customer trust.

    Kohdistuu: Healthcare and commercial installations

  2. Dependence on new distribution partners in commercial marketsVaikutus: KorkeaTodennäköisyys: Kohtalainen

    After the Donastar termination, commercial sales growth depends on partner execution.

    KohdistuuFoodBeverageHospitality markets
  3. Regulatory compliance and FDA oversightVaikutus: KorkeaTodennäköisyys: Kohtalainen

    Medical-use products are subject to testing, labeling, distribution, and approval rules.

    Kohdistuu: Ultrafilters used in healthcare settings

  4. Supply-chain dependence on third-party product suppliersVaikutus: KeskitasoTodennäköisyys: Kohtalainen

    The company is vulnerable to supply disruptions and price fluctuations.

    Kohdistuu: Product sourcing and inventory availability

  5. Demand volatility in emergency-response salesVaikutus: KeskitasoTodennäköisyys: Kohtalainen

    Management noted elevated emergency-response sales may not persist.

    Kohdistuu: Quarterly revenue mix

Kysy Clarifolta: Nephros, Inc

Kirjanpito

Harkinnanvaraiset erät
Point-in-time revenue recognition

Shipping-based recognition makes revenue sensitive to order timing and logistics.

Vaikutus: Quarterly revenue and margin volatility

Variable consideration estimates

Discounts, returns, and allowances reduce recognized revenue.

Vaikutus: Net revenue and gross margin

Inventory reserves and write-offs

Management cited lower inventory reserves as a margin driver in 2025.

Vaikutus: Gross profit and operating income

Goodwill and intangible asset impairment

Finite-lived intangibles and goodwill require periodic impairment testing.

Vaikutus: Non-cash charges to earnings

Stock-based compensation

Share-based awards affect SG&A and can create period-to-period noise.

Vaikutus: Operating expense and net income

Samankaltaisia listattuja yhtiöitä

Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.

Waters Corporation

WAT · Laboratory Analytical Instruments

Nuwellis, Inc.

NUWE · Electromedical & Electrotherapeutic Apparatus

Fresenius Medical Care AG

FMS · Services-Misc Health & Allied Services, NEC

Kairos Pharma, LTD.

KAPA · Pharmaceutical Preparations

Veralto Corp

VLTO · Instruments For Meas & Testing of Electricity & Elec Signals

DuPont de Nemours, Inc.

DD · Plastic Materials, Synth Resins & Nonvulcan Elastomers

Päivitetty: 24.9.2026

Nephros, Inc (NEPH) liikevaihto, tulos ja tunnusluvut 2025 – Clarifo